Guided Therapeutics (GTHP) Current Leases (2019 - 2025)
Guided Therapeutics (GTHP) reported Current Leases of $45000.0 for Q4 2025, down 57.55% on a YoY basis from $106000.0 in Q4 2024, and down 40.79% sequentially from $76000.0 in Q3 2025.
Guided Therapeutics (GTHP) Current Leases (2019 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 7 years of Current Leases data on file, last reported at $45000.0 in Q4 2025.
- For the quarter ending Q4 2025, Current Leases fell 57.55% year-over-year to $45000.0; the trailing twelve-month figure through Dec 2025 stood at $45000.0 (down 57.55% YoY), and the FY2025 full-year result was $45000.0, down 57.55% from the prior year.
- Current Leases declined to $45000.0 in Q4 2025, from $76000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $110000.0 in Q1 2025 to a low of $42000.0 in Q1 2021.
- A 5-year average of $80800.0 and a median of $80500.0 in 2022 frame the typical range for Current Leases.
- Across the five-year window, Current Leases sank 57.58% in 2021 and surged 66.67% in 2022, its largest moves.
- Tracing GTHP's Current Leases over 5 years: stood at $67000.0 in 2021, then grew by 17.91% to $79000.0 in 2022, then climbed by 15.19% to $91000.0 in 2023, then gained by 16.48% to $106000.0 in 2024, then sank by 57.55% to $45000.0 in 2025.
- Business Quant data shows GTHP's Current Leases at $45000.0 in Q4 2025, $76000.0 in Q3 2025, and $104000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 24.30 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 20.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | 45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Jun 30, 2025 | 104,000.00 |
| Mar 31, 2025 | 110,000.00 |
| Dec 31, 2024 | 106,000.00 |
| Sep 30, 2024 | 102,000.00 |
| Jun 30, 2024 | 99,000.00 |
| Mar 31, 2024 | 95,000.00 |
| Dec 31, 2023 | 91,000.00 |
| Sep 30, 2023 | 88,000.00 |
| Jun 30, 2023 | 85,000.00 |
| Mar 31, 2023 | 82,000.00 |
| Dec 31, 2022 | 79,000.00 |
| Sep 30, 2022 | 76,000.00 |
| Jun 30, 2022 | 73,000.00 |
| Mar 31, 2022 | 70,000.00 |
| Dec 31, 2021 | 67,000.00 |
| Sep 30, 2021 | 64,000.00 |
| Jun 30, 2021 | 62,000.00 |
| Mar 31, 2021 | 42,000.00 |